Gary D. Berman
Experienced in Allergic Conjunctivitis

Dr. Gary D. Berman

Allergy and Immunology
Allergy And Asthma Specialists, PA
825 Nicollet Mall, Suite 1149, 
Minneapolis, MN 
 (691.9 mi)
Clinical Trials:Currently Recruiting for 2 Trials
Accepting New Patients
Offers Telehealth
Experienced in Allergic Conjunctivitis
Allergy And Asthma Specialists, PA
825 Nicollet Mall, Suite 1149, 
Minneapolis, MN 
 (691.9 mi)
OverviewInsuranceLocationsClinical Research

Overview

Gary Berman is an Allergy and Immunologist in Minneapolis, Minnesota. Dr. Berman and is rated as an Experienced provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Giant Papillary Conjunctivitis, Allergic Rhinitis, Grass Allergy, and Sinusitis. Dr. Berman is currently accepting new patients.

His clinical research consists of co-authoring 16 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Allergic Conjunctivitis.

Specialties
Allergy and Immunology
Licenses
Clinical & Laboratory Immunology in MN
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Medica
  •  Humana

Locations

ALLERGY AND ASTHMA SPECIALISTS, PA
825 Nicollet Mall, Suite 1149, Minneapolis, MN 55402

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age With Episodic Migraine - the REBUILD-1 Study
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adolescent Patients 12 to 17 Years of Age With Chronic Migraine - the REBUILD-2 Study
Enrollment Status: Recruiting
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drug: Galcanezumab
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine
Enrollment Status: Completed
Publish Date: November 28, 2023
Intervention Type: Drug
Study Drug: LY3451838
Study Phase: Phase 2
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
A 12-month Prospective, Randomized, Interventional, Global, Multi-center, Active-controlled Study Comparing Sustained Benefit of Two Treatment Paradigms (AMG334 qm vs. Oral Prophylactics) in Adult Episodic Migraine Patients
Enrollment Status: Completed
Publish Date: November 18, 2023
Intervention Type: Drug
Study Drugs: Erenumab, Oral Prophylactic
Study Phase: Phase 4
Clinical Evaluation of Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches
Clinical Evaluation of Avulux® Lenses as an Aid in Reducing the Impact of Migraine Headaches
Enrollment Status: Completed
Publish Date: January 09, 2023
Intervention Type: Other, Device
Study Phase: Not Applicable
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
A Long-Term, Open-Label Study to Evaluate the Safety of M207 (Zolmitriptan Intracutaneous Microneedle System) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: August 19, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Adults With Treatment-Resistant Migraine - the CONQUER Study
Enrollment Status: Completed
Publish Date: July 08, 2020
Intervention Type: Drug
Study Phase: Phase 3
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
A Study of Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute TReaTment of MigrAiNe: A Randomized, Double-blind, Placebo-controlled Parallel Group Study (SPARTAN)
Enrollment Status: Completed
Publish Date: September 23, 2019
Intervention Type: Drug
Study Phase: Phase 3
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Randomized, Double-blind, Multi-center, Parallel-group, Dose-ranging Comparison of the Safety and Efficacy of the ZP-Zolmitriptan Intracutaneous Microneedle Systems to Placebo for the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: March 13, 2018
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
View 7 Less Clinical Trials

16 Total Publications

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.
Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents.
Journal: Human vaccines & immunotherapeutics
Published: January 21, 2025
Similar Doctors
Advanced in Allergic Conjunctivitis
Dr. Alaaddin H. Kandeel
Allergy and Immunology
Advanced in Allergic Conjunctivitis
Dr. Alaaddin H. Kandeel
Allergy and Immunology

Ridgeview Medical Center

7907 Powers Blvd, 
Chanhassen, MN 
 (15.6 mi)
952-934-0570
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients

Alaaddin Kandeel is an Allergy and Immunologist in Chanhassen, Minnesota. Dr. Kandeel and is rated as a Distinguished provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Allergic Rhinitis, Sinusitis, Angioedema, and Food Allergy. Dr. Kandeel is currently accepting new patients.

Experienced in Allergic Conjunctivitis
Dr. John B. Sweet
Allergy and Immunology
Experienced in Allergic Conjunctivitis
Dr. John B. Sweet
Allergy and Immunology

Hennepin Healthcare System Inc

5653 Duluth St, 
Golden Valley, MN 
 (4.1 mi)
612-873-6963
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

John Sweet is an Allergy and Immunologist in Golden Valley, Minnesota. Dr. Sweet and is rated as an Advanced provider by MediFind in the treatment of Allergic Conjunctivitis. His top areas of expertise are Sinusitis, Allergic Rhinitis, Hives, and Vibratory Urticaria. Dr. Sweet is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile